AI Article Synopsis
- The study investigated the link between serum levels of hepatocyte growth factor (HGF) and interferon (IFN) therapy in 94 chronic hepatitis C patients treated from 1994 to 1996.
- Serum HGF levels were assessed before and after IFN treatment, showing a decrease in most patients, especially in those who responded virologically.
- The findings suggest that tracking serum HGF can help evaluate liver tissue changes post-IFN therapy, indicating its potential clinical significance.
Article Abstract
In this study, the serum concentrations of human hepatocyte growth factor (HGF) were examined to clarify the relationship between HGF and interferon (IFN) therapy for hepatitis C. The subjects were 94 patients with chronic hepatitis C who underwent liver biopsy at our institution from 1994 through 1996. These patients were treated with natural IFN-alpha, IFNalpha(2a) and IFNalpha(2b) for periods varying from 12 to 26 weeks. Serum levels of HGF were determined in individual patients just before and after the administration of IFN and at 6 months and 1 year thereafter. The serum concentration of HGF was evaluated using enzyme-linked immunosorbent assay kits. The intra-hepatic location of HGF was explored using an immunoperoxidase-staining method. A positive correlation was found between the degree of HGF expression in the liver and the serum HGF concentrations. The degree of HGF expression in the liver decreased in the virologically sustained responders (SVRs) following IFN therapy. The serum HGF concentrations immediately after IFN therapy were lower than those before therapy in 83% of the patients. The concentrations gradually rose thereafter in about 45% of the non-responders, while it remained low or declined further in about half of the patients in this group. In the SVRs, the serum HGF concentrations declined in 88% of patients immediately after IFN therapy. Thereafter, it remained equally low or declined further in 60% of the SVRs. The serum HGF concentrations at 6 months and 1 year after IFN therapy were significantly lower in the SVRs than in the non-responders. In conclusions, serum HGF concentrations declined following IFN treatment regardless of the virological outcome of treatment. The decrease in serum HGF concentrations results from a decrease in the number of mesenchymal cells producing HGF. Consequently, evaluation of the serum HGF concentration is of clinical value for assessing changes in liver tissues after IFN therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000084599 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mucin5AC promotes breast cancer brain metastasis through cMET/CD44v6.
Clin Cancer Res
January 2025
University of Nebraska Medical Center, OMAHA, NE, United States.
Purpose: Breast cancer (BC) brain metastasis (BrM) remains a significant clinical problem. Mucins have been implicated in metastasis; however, if they are also involved in BCBrM remains unknown. We queried BrM patient databases and found Mucin 5AC (MUC5AC) to be upregulated and therefore sought to define the role of MUC5AC in BCBrM.
View Article and Find Full Text PDFMatched serum- and urine-derived biomarkers of interstitial cystitis/bladder pain syndrome.
PLoS One
December 2024
Institute of Cell Biology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Setting up the correct diagnosis of interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder, is a challenge, as there are neither diagnostic criteria nor reliable and non-invasive disease biomarkers available. The aim of the present study was to simultaneously determine matched serum- and urine-derived biomarkers of IC/BPS, which would provide additional insights into disease mechanisms and set the basis for further biomarker validation. Our study included 12 female patients with IC/BPS and 12 healthy controls.
View Article and Find Full Text PDFComparison of Corneal Epitheliotrophic Factors of Undiluted Autologous Platelet-Rich Plasma and Autologous Serum Eye Drops for Dry Eye Disease.
Ophthalmol Ther
December 2024
Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Introduction: The purpose of this study was to compare the growth factor concentrations in undiluted autologous platelet-rich plasma (APRP) and autologous serum (AS) eye drops.
Methods: This was a single-center, prospective trial conducted in a tertiary university hospital in Bangkok, Thailand. Ninety-six patients with moderate-to-severe dry eye disease, who were randomly assigned to receive either 100% APRP or 100% AS, were enrolled in the study.
Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy.
Ann Oncol
December 2024
Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Department of Medicine, Immunology and Allergy Service, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland. Electronic address:
Article Synopsis
- The study identifies biomarkers that can differentiate between immune-related cytokine release syndrome (irCRS) and sepsis in oncology patients undergoing immune checkpoint inhibitor therapy.
- The analysis revealed that hepatocyte growth factor (HGF) and ferritin are particularly effective in predicting outcomes related to irHLH and Grade 3 irCRS, with a 100% positive and negative predictive value.
- Patients with severe irCRS who did not respond to corticosteroids showed complete resolution after treatment with tocilizumab (TCZ), highlighting the potential for targeted therapies in these cases.
Article Synopsis
- The study examined 33 severe COVID-19 patients who underwent a novel hemoperfusion therapy using the Seraph100 filter, aiming to reduce viral RNA levels and markers of inflammation.
- Results showed that while the initial levels of SARS-CoV-2 RNA were generally low and did not significantly change post-treatment, five inflammatory protein analytes exhibited notable decreases, indicating some therapeutic effect on inflammation and endothelial damage.
- The conclusion highlighted that Seraph 100 did not effectively lower viral RNA levels, but it did successfully reduce several inflammatory markers in the blood of these patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!